ATE412407T1 - Arzneimittel zubereitung enthaltend 2-amino-2-ä2- (4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid - Google Patents

Arzneimittel zubereitung enthaltend 2-amino-2-ä2- (4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid

Info

Publication number: ATE412407T1
Authority: AT; Austria
Prior art keywords: octylphenyl; saccharide; lecithin; diol; amino
Prior art date: 1997-02-27

Application number

AT98905636T

Other languages

English (en)

Inventor

Atsushi Sakai

Rumiko Masuda

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-02-27

Filing date

1998-02-25

Publication date

2008-11-15

1998-02-25 Application filed by Novartis Ag filed Critical Novartis Ag

2008-11-15 Application granted granted Critical

2008-11-15 Publication of ATE412407T1 publication Critical patent/ATE412407T1/de

Links

IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 title abstract 2
150000001720 carbohydrates Chemical class 0.000 title abstract 2
229940067606 lecithin Drugs 0.000 title abstract 2
235000010445 lecithin Nutrition 0.000 title abstract 2
239000000787 lecithin Substances 0.000 title abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
238000010322 bone marrow transplantation Methods 0.000 abstract 1
KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
239000007788 liquid Substances 0.000 abstract 1
210000000056 organ Anatomy 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000001629 suppression Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Inorganic Chemistry (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Biophysics (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT98905636T 1997-02-27 1998-02-25 Arzneimittel zubereitung enthaltend 2-amino-2-ä2- (4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid ATE412407T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP4366897		1997-02-27

Publications (1)

Publication Number	Publication Date
ATE412407T1 true ATE412407T1 (de)	2008-11-15

Family

ID=12670236

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98905636T ATE412407T1 (de)	1997-02-27	1998-02-25	Arzneimittel zubereitung enthaltend 2-amino-2-ä2- (4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid

Country Status (18)

Country	Link
US (1)	US6277888B1 (de)
EP (2)	EP2030614A1 (de)
JP (1)	JP4153563B2 (de)
KR (1)	KR20000075745A (de)
CN (1)	CN1178653C (de)
AT (1)	ATE412407T1 (de)
AU (1)	AU735406B2 (de)
BR (1)	BR9811453A (de)
CA (1)	CA2282378C (de)
DE (1)	DE69840169D1 (de)
DK (1)	DK0990440T3 (de)
ES (1)	ES2317663T3 (de)
IL (1)	IL131608A (de)
NZ (1)	NZ337823A (de)
PT (1)	PT990440E (de)
RU (1)	RU2188004C2 (de)
SI (1)	SI0990440T1 (de)
WO (1)	WO1998037875A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9624038D0 (en) *	1996-11-19	1997-01-08	Sandoz Ltd	Organic compounds
JP4627356B2 (ja) *	1999-06-30	2011-02-09	昭松森	ウイルス性心筋炎の予防または治療薬剤
WO2002018395A1 (en)	2000-08-31	2002-03-07	Merck & Co., Inc.	Phosphate derivatives as immunoregulatory agents
BR0306811A (pt) *	2002-01-11	2004-10-26	Sankyo Co	Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
CA2521325C (en) *	2003-04-08	2010-09-14	Novartis Ag	Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
RU2233163C1 (ru) *	2003-04-30	2004-07-27	Государственное учреждение "Нижегородский научно-исследовательский кожно-венерологический институт"	Способ лечения акантолитической пузырчатки
GB0329498D0 (en) *	2003-12-19	2004-01-28	Novartis Ag	Organic compounds
JP2005272453A (ja)	2004-02-24	2005-10-06	Sankyo Co Ltd	アミノアルコール化合物
MX2007001236A (es) *	2004-07-30	2007-03-23	Novartis Ag	Formulaciones de compuestos de 2-amino-1, 3-propanodiol.
KR20140095109A (ko) *	2004-11-29	2014-07-31	노파르티스 아게	Ｓ１ｐ 수용체 효능제의 투여 용법
EP1679065A1 (de)	2005-01-07	2006-07-12	OctoPlus Sciences B.V.	Zubereitung mit kontrollierter Freisetzung von Interferon auf PEGT/PBT-Block-Copolymer-Basis
SI2295049T1 (sl) *	2005-09-09	2015-03-31	Novartis Ag	Zdravljenje avtoimunskih bolezni
EP1923055A1 (de) *	2006-09-26	2008-05-21	Novartis AG	Gefriergetrocknete pharmazeutische Zusammensetzung mit einem S1P Agonisten oder Modulator
AU2011235934A1 (en) *	2006-09-26	2011-11-03	Novartis Ag	Pharmaceutical compositions comprising an S1P modulator
AU2008310846C1 (en)	2007-10-12	2022-10-06	Novartis Ag	Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
HUE033168T2 (en)	2008-03-17	2017-11-28	Actelion Pharmaceuticals Ltd	Dosage regimen for selective SIP1 receptor agonist
AR085749A1 (es)	2011-04-01	2013-10-23	Novartis Ag	Formulaciones
RU2483749C2 (ru) *	2011-04-15	2013-06-10	Леонид Леонидович Клопотенко	Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде биопленки
RU2483748C2 (ru) *	2011-04-15	2013-06-10	Леонид Леонидович Клопотенко	Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде пластыря
HK1198467A1 (en)	2011-08-03	2015-05-08	Zhongmin MA	Treatment of type 2 diabetes with fty720
EP3027174B1 (de) *	2013-07-29	2019-07-24	Aizant Drug Research Solutions Private Limited	Pharmazeutische zusammensetzungen von fingolimod
GR1009654B (el)	2018-08-31	2019-11-18	Φαρματεν Α.Β.Ε.Ε.	Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5612993B2 (de)	1973-09-03	1981-03-25
US4020159A (en) *	1974-10-08	1977-04-26	Apotheker A. Herbert K.G., Fabrik Pharmazeutischer Praparate Wiesbaden	Methods of and medications for treating cardiac disorders by using strophanthin
JPS5562010A (en)	1978-10-31	1980-05-10	Ajinomoto Co Inc	Fat emulsion for intravenous injection
AU5078885A (en) *	1984-12-20	1986-06-26	Warner-Lambert Company	Non-irritant detergent
JPS61172814A (ja)	1985-01-25	1986-08-04	Ss Pharmaceut Co Ltd	安定な低溶血性ビタミンｅ注射液
JPS63152327A (ja) *	1987-11-20	1988-06-24	Toyama Chem Co Ltd	脂肪乳剤から成る溶血防止用組成物を含有する製剤
JPH01172814A (ja)	1987-12-26	1989-07-07	Canon Inc	レーザーユニット
AU6461090A (en)	1989-10-30	1991-05-02	Abbott Laboratories	Injectable formulation for lipophilic drugs
US5091188A (en) *	1990-04-26	1992-02-25	Haynes Duncan H	Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
JPH04173736A (ja)	1990-11-06	1992-06-22	Nippon Shinyaku Co Ltd	乳化剤
US5604229A (en) *	1992-10-21	1997-02-18	Yoshitomi Pharmaceutical Industries, Ltd.	2-amino-1,3-propanediol compound and immunosuppressant
JPH06340525A (ja)	1993-06-02	1994-12-13	Lion Corp	安定な低眼刺激性ビタミンａ類可溶化点眼剤
US5683693A (en) *	1994-04-25	1997-11-04	Trustees Of Dartmouth College	Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
DE69524962D1 (de)	1994-08-22	2002-02-14	Welfide Corp	Benzolderivate und deren medizinische verwendung
JP3169807B2 (ja)	1995-09-18	2001-05-28	本田技研工業株式会社	ロータ組み付け装置
ES2230571T3 (es) *	1995-12-28	2005-05-01	Mitsubishi Pharma Corporation	`composicion farmaceutica destinada para la administracion topica que comprende el 2-amino-2-(2-(4-octilfenil)etil) propan-1,3-diol para el tratamiento de las enfermedades causadas por una alteracion inmunitaria.
JP2002241272A (ja) *	1996-07-18	2002-08-28	Mitsubishi Pharma Corp	医薬処方組成物
KR100190826B1 (ko) *	1996-08-26	1999-06-01	강재헌	적혈구 용혈 억제용 약제학적 조성물 및 그의제조방법

1998
- 1998-02-25 DE DE69840169T patent/DE69840169D1/de not_active Expired - Lifetime
- 1998-02-25 SI SI9830915T patent/SI0990440T1/sl unknown
- 1998-02-25 PT PT98905636T patent/PT990440E/pt unknown
- 1998-02-25 BR BR9811453-0A patent/BR9811453A/pt not_active Application Discontinuation
- 1998-02-25 ES ES98905636T patent/ES2317663T3/es not_active Expired - Lifetime
- 1998-02-25 KR KR1019997007815A patent/KR20000075745A/ko not_active Ceased
- 1998-02-25 DK DK98905636T patent/DK0990440T3/da active
- 1998-02-25 JP JP53750798A patent/JP4153563B2/ja not_active Expired - Fee Related
- 1998-02-25 EP EP08162705A patent/EP2030614A1/de not_active Withdrawn
- 1998-02-25 US US09/380,274 patent/US6277888B1/en not_active Expired - Lifetime
- 1998-02-25 WO PCT/JP1998/000755 patent/WO1998037875A1/ja not_active Ceased
- 1998-02-25 EP EP98905636A patent/EP0990440B1/de not_active Expired - Lifetime
- 1998-02-25 RU RU99120398/14A patent/RU2188004C2/ru not_active IP Right Cessation
- 1998-02-25 NZ NZ337823A patent/NZ337823A/en not_active IP Right Cessation
- 1998-02-25 AT AT98905636T patent/ATE412407T1/de active
- 1998-02-25 CN CNB988045257A patent/CN1178653C/zh not_active Expired - Fee Related
- 1998-02-25 IL IL13160898A patent/IL131608A/xx not_active IP Right Cessation
- 1998-02-25 CA CA002282378A patent/CA2282378C/en not_active Expired - Fee Related
- 1998-02-25 AU AU61155/98A patent/AU735406B2/en not_active Ceased

Also Published As

Publication number	Publication date
US6277888B1 (en)	2001-08-21
CN1253499A (zh)	2000-05-17
DE69840169D1 (de)	2008-12-11
AU735406B2 (en)	2001-07-05
BR9811453A (pt)	2000-09-12
HK1027039A1 (en)	2001-01-05
EP0990440A1 (de)	2000-04-05
EP0990440A4 (de)	2004-04-21
WO1998037875A1 (fr)	1998-09-03
ES2317663T3 (es)	2009-04-16
IL131608A0 (en)	2001-01-28
SI0990440T1 (sl)	2009-04-30
CA2282378A1 (en)	1998-09-03
KR20000075745A (ko)	2000-12-26
CN1178653C (zh)	2004-12-08
RU2188004C2 (ru)	2002-08-27
HK1027959A1 (en)	2001-02-02
AU6115598A (en)	1998-09-18
EP0990440B1 (de)	2008-10-29
DK0990440T3 (da)	2009-02-23
IL131608A (en)	2003-02-12
NZ337823A (en)	2001-04-27
EP2030614A1 (de)	2009-03-04
PT990440E (pt)	2009-02-05
CA2282378C (en)	2008-12-30
JP4153563B2 (ja)	2008-09-24

Legal Events

Date

Code

Title

Description

2009-06-15

UEP

Publication of translation of european patent specification

Ref document number: 0990440

Country of ref document: EP

Publication	Publication Date	Title
ATE412407T1 (de)	2008-11-15	Arzneimittel zubereitung enthaltend 2-amino-2-ä2- (4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid
PT812588E (pt)	2005-01-31	Composicao farmaceutica externa para administracao topica contendo 2-amino-2-(2-(4-octilfenil)-etil)-propano-1,3-diol para o tratamento de doencas provocadas por uma afeccao imunitaria
PT1050301E (pt)	2009-06-16	Composições medicinais contendo 2-amino-2-[2-(4- octilfenil)etil]propano-1,3-diol
BR9507656A (pt)	1997-09-23	Composto utilização de um composto composição farmacéutica e processos para o tratamento de um paciente que sofre de dor e para a preparação de um composto
DE59902055D1 (de)	2002-08-22	Zweiteilige kapsel zur aufnahme von pharmazeutischen zubereitungen für pulverinhalatoren
ES2179910T3 (es)	2003-02-01	Modificacion cristalina del cdch, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
RU99120398A (ru)	2001-07-20	Фармацевтическая композиция
ATE316779T1 (de)	2006-02-15	Implantate zur gesteuerten freisetzung von pharmazeutischen wirkstoffen und verfahren zur herstellung
HUP0004375A2 (hu)	2001-08-28	Azelainsavat tartalmazó kompozíció
ITRM940570A0 (it)	1994-09-08	"sale della l-carnitina e composizioni farmaceutiche che lo contengonoper il trattamento di affezioni cutanee"
HUP0202525A2 (hu)	2002-11-28	Mofetil mikofenolát és PEG-IFN-alfa együttes alkalmazása, valamint az azokat tartalmazó gyógyszerkészítmények és kit
BR0010983A (pt)	2002-03-05	Preparações para a aplicação de agentes antiinflamatórios
ATE174798T1 (de)	1999-01-15	Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
FI982689L (fi)	1998-12-11	2-fenyyli-1,2-bentsoisoselenatsol-3(2H)-onin käyttö Alzheimerin taudin käsittelyyn tarkoiettujen farmaseuttisten valmisteiden valmistukseen
NO172537C (no)	1993-08-04	Analogifremgangsmaate til fremstilling av terapeutisk aktive 3-desmetyl-4-fluor-mevalonsyrederivater
CA2340734A1 (en)	2000-06-22	Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
FR2456104A1 (fr)	1980-12-05	Nouvelles pyrazinobenzodiazepines, leur preparation et leur application comme medicaments
ITRM940571A0 (it)	1994-09-08	"sale della l-carnitina e composizioni farmaceutiche che lo contengonoper il trattamento di affezioni cutanee"
NO883468D0 (no)	1988-08-04	Fremgangsmaate til fremstilling av farmasoeytiske blandinger inneholdende cyklopeptider som reserpsjonsbefordrere ved applikasjon paa slimhuden.
HUP9901303A2 (hu)	1999-09-28	Gyógyszerkészítmény autoimmun betegségek kezelésére
ES2044170T3 (es)	1994-01-01	Sal de estroncio, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen.
BR9810452A (pt)	2000-09-05	Nova combinação de medicamentos contra asma
NO168173C (no)	1992-01-22	Analogifremgangsmaate ved fremstilling av terapeutisk aktive 5-oxo-1-imidazolidinacetamid-derivater
EA199900226A1 (ru)	1999-08-26	Фармацевтические композиции для лечения вирусных заболеваний
NO20001895D0 (no)	2000-04-12	Anvendelse av glykosaminoglykaner for fremstilling av farmasøytiske preparater for behandling av diabetes assosierte- øyesykdommer